Evonik Sees 2026 Earnings at Upper End of €2.0 Billion to €2.2 Billion Range
Key Facts
Evonik expects its 2026 adjusted earnings before interest, taxes, depreciation and amortization to come in at the upper end of its range of €2.0 billion to €2.2 billion, according to wording in a Reuters brief dated November 3. The range was raised in June from €1.7 billion to €2.0 billion, according to the company’s second-quarter statement. But the available official materials do not establish that the company raised or narrowed the range again, so an outlook at its upper end does not mean there has been a new change in guidance. The evidence did not include third-quarter earnings figures or the size of any gap versus analysts’ estimates, although the Reuters brief’s headline indicates that underlying earnings came in below estimates. Accordingly, the available information centers on the year-end outlook and the context of past performance, rather than a detailed measure of third-quarter results.
In the second quarter of 2026, adjusted earnings before interest, taxes, depreciation and amortization rose 24% to €630 million, according to Evonik’s statement. Revenue increased 11% year on year, with sales volumes up 7% and prices up 7%, the company said. These indicators provide context for the range underpinning the full-year outlook, as revenue growth coincided with increases in both volumes and prices. Net income, however, moved in the opposite direction in the same quarter, reaching €84 million compared with €120 million in the second quarter of 2025. The comparison shows that gains in adjusted earnings and revenue did not coincide with an increase in net income over the same period, according to the published figures.
Evonik attributed some of the favorable conditions in the second quarter to supply-chain disruptions linked to the conflict in the Middle East, which caused bottlenecks, particularly outside Europe. The company said these disruptions resulted in an “exceptional economic gain.” But in its initial announcement of second-quarter results, it said the positive situation could weaken later in the year as maritime shipping stabilized after the reopening of the Strait of Hormuz. By contrast, it expected positive momentum in the animal nutrition business to continue in the third quarter. This places the upper-end earnings outlook in the context of factors the company said had varying effects across periods and businesses, without by itself establishing the cause of third-quarter results or the contribution of each factor.
Evonik’s performance at the start of the year was weaker than its second-quarter results: first-quarter sales fell 9% to €3.427 billion, and adjusted earnings before interest, taxes, depreciation and amortization declined 15% to €475 million compared with the first quarter of 2025, according to its quarterly statement. The company attributed the weakness to continued subdued demand across its key end markets worldwide. It added that economic uncertainty, exacerbated by the war in the Middle East, was accompanied by an improvement in business activity since March. The shift from a first-quarter decline to an increase in adjusted earnings in the second quarter reflects differing conditions between the two periods, while the full-year outlook remains based on the earnings range the company announced in June.
The company is continuing its “Evonik Tailor Made” restructuring program, which it said will cut about 2,800 jobs between 2024 and 2026. The plan includes an extension that involves a further reduction of about 3,200 jobs during 2027–2029, according to the second-quarter statement. The figures outline a program extending beyond the current fiscal year, but the evidence does not specify the savings achieved or the program’s financial impact on third-quarter earnings or the 2026 outlook. Job cuts therefore remain part of the announced restructuring context, without attributing improved profitability to them unless the company provides figures linking the two. The program comes alongside the varying demand and supply conditions the company described in its quarterly statements.
Evonik’s calendar lists March 4, 2027, as the release date for its fourth-quarter 2026 report. This is the next date in the evidence for a quarterly company report, following the third-quarter results covered in the Reuters brief on November 3. The upcoming report will be part of the monitoring of the annual earnings range of €2.0 billion to €2.2 billion, which the company said in June it expected after raising it from €1.7 billion to €2.0 billion. The available materials here do not include the full numerical details of third-quarter results or their comparison with analysts’ estimates.